<DOC>
	<DOCNO>NCT00293436</DOCNO>
	<brief_summary>RATIONALE : Celecoxib erlotinib may stop growth tumor cell block enzyme need growth . Celecoxib may also stop growth liver cancer block blood flow tumor . PURPOSE : This phase I/II trial study side effect best dose give celecoxib together erlotinib see well work treat patient liver cancer .</brief_summary>
	<brief_title>Celecoxib Erlotinib Treating Patients With Liver Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine safety adjuvant celecoxib erlotinib hydrochloride patient hepatocellular carcinoma ( HCC ) high risk recurrence . ( phase I ) - Assess disease-free overall survival patient treat adjuvant celecoxib erlotinib hydrochloride . ( phase II ) Secondary - Determine maximum tolerate dose celecoxib erlotinib hydrochloride phase II portion trial . ( phase I ) OUTLINE : This phase I , dose-escalation study follow open-label , phase II study . Patients assign treatment accord Child-Pugh class cirrhosis ( class A/noncirrhotic v class B ) . - Phase I : Patients receive oral celecoxib twice daily oral erlotinib hydrochloride daily . Treatment continue 6 month absence disease progression unacceptable toxicity . Cohorts 3-6 patient receive escalate dos celecoxib erlotinib hydrochloride maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 6 patient experience dose-limiting toxicity . Separate dose escalation conduct 2 group accord liver dysfunction . - Phase II : Patients receive celecoxib erlotinib hydrochloride phase I MTD . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histological evidence hepatocellular carcinoma ( HCC ) No evidence residual recurrent disease Received 1 follow therapy : Tumor resection 48 week prior study enrollment Transarterial chemoembolization past 48 week Radiofrequency ablation percutaneous ethanol injection ( sequential combination thereof ) past 28 week Meets 1 follow highrisk feature recurrence : History resection single HCC &gt; 5 cm History multifocal HCC ( include microsatellite disease find time resection ) History vascular invasion ( macro micro ) History poorly differentiate HCC Underlying cirrhosis No ChildPugh class C cirrhosis PATIENT CHARACTERISTICS : Absolute neutrophil count &gt; 1,500/mm^3 Platelet count ≥ 75,000/mm^3 Hemoglobin ≥ 9.0 g/dL Creatinine ≤ 2.0 mg/dL Bilirubin ≤ 2.0 mg/dL AST/ALT ≤ 3 time upper limit normal ( ULN ) Alkaline phosphatase ≤ 3 time ULN INR ≤ 1.5 time ULN Albumin ≥ 2.5 g/dL ECOG performance status 02 Life expectancy ≥ 2 year Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 6 month completion study treatment No malignancy within past 5 year except nonmelanoma skin cancer Patients must agree wear contact lenses No history ulcer disease gastrointestinal bleeding No myocardial infarction within past 18 month No cerebral vascular event within past 18 month No history aspirin NSAIDinduced asthma No history Gilbert 's syndrome No history hypersensitivity reaction allergy sulfa drug , aspirin , NSAIDs No liver transplantation candidate phase I portion study No New York Heart Association class III IV cardiac disease No interstitial lung disease No gastrointestinal disease prohibit oral medication require IV alimentation No active peptic ulcer disease No unstable angina pectoris No ongoing , active , untreated infection No hypersensitivity celecoxib No rise alphafetal protein ( AFP ) attributable hepatitis B C virus No psychiatric illness social situation would preclude study compliance PRIOR CONCURRENT THERAPY : No prior liver transplantation No prior chemotherapy biologic therapy adjuvant set No prior chest mantle radiotherapy No concurrent aspirin nonsteroidal antiinflammatory drug ( NSAID ) No concurrent interferon No concurrent oral steroid No concurrent anticoagulant therapy No concurrent CYP3A4 inducer inhibitors No concurrent commercial investigational anticancer agent therapies No concurrent selective cyclooxygenase2 inhibitor No concurrent antineoplastic antitumor agent , include chemotherapy , radiotherapy , immunotherapy , hormonal anticancer therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>adult primary hepatocellular carcinoma</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>localize resectable adult primary liver cancer</keyword>
</DOC>